Abstract
Objective: There is a decreased risk of breast cancer in systemic lupus erythematosus (SLE) versus the general population; little is known regarding the receptor status of breast cancers in SLE, or treatment. Methods: Breast cancer cases occurring after SLE diagnosis were ascertained through linkage with tumor registries. We determined breast cancer positivity for estrogen receptors (ER), progesterone receptors (PR), and/or Human Epidermal Growth Factor Receptor 2 (HER2), as well as cancer treatment. Results: We obtained information on ER, PR, and/or HER2 status for 63 SLE patients with breast cancer. Fifty-three had information on ER and/or PR status; 36 of these (69%) were ER positive. Thirty-six of the 63 had information on HER2 status; of these, 26 had complete information on all three receptors. Twenty-one of these 26 (81%) were HER2 negative; seven of 26(27%) were triple negative. All but one patient underwent surgery; 11.5% received both non-tamoxifen chemotherapy and radiotherapy, 16.4% radiotherapy without non-tamoxifen chemotherapy, and 14.7% received non-tamoxifen chemotherapy without radiotherapy. Conclusion: ER positivity was similar to historical general population figures, with a trend toward a higher proportion of triple-negative breast cancers in SLE (possibly reflecting the relatively young age of our SLE patients).
Original language | English (US) |
---|---|
Pages (from-to) | 120-123 |
Number of pages | 4 |
Journal | Lupus |
Volume | 27 |
Issue number | 1 |
DOIs | |
State | Published - Jan 1 2018 |
Funding
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: A National institutes of Health (NIH) AR 43727 grant has been awarded to Dr Petri.
Keywords
- Breast cancer
- estrogen
- progesterone
- receptor
- systemic lupus erythematosus
ASJC Scopus subject areas
- Rheumatology